- Home
- OUSTW vs PTIX Comparison
OUSTW vs PTIX Comparison
Compare OUSTW & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUSTW
- PTIX
- Stock Information
- Founded
- OUSTW N/A
- PTIX 1994
- Country
- OUSTW United States
- PTIX United States
- Employees
- OUSTW N/A
- PTIX N/A
- Industry
- OUSTW Industrial Machinery/Components
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- OUSTW Industrials
- PTIX Health Care
- Exchange
- OUSTW Nasdaq
- PTIX Nasdaq
- Market Cap
- OUSTW 3.1M
- PTIX 3.7M
- IPO Year
- OUSTW N/A
- PTIX 2016
- Fundamental
- Price
- OUSTW $0.05
- PTIX $0.44
- Analyst Decision
- OUSTW
- PTIX
- Analyst Count
- OUSTW 0
- PTIX 0
- Target Price
- OUSTW N/A
- PTIX N/A
- AVG Volume (30 Days)
- OUSTW N/A
- PTIX 377.2K
- Earning Date
- OUSTW N/A
- PTIX 11-14-2024
- Dividend Yield
- OUSTW N/A
- PTIX N/A
- EPS Growth
- OUSTW N/A
- PTIX N/A
- EPS
- OUSTW N/A
- PTIX N/A
- Revenue
- OUSTW N/A
- PTIX N/A
- Revenue This Year
- OUSTW N/A
- PTIX N/A
- Revenue Next Year
- OUSTW N/A
- PTIX N/A
- P/E Ratio
- OUSTW N/A
- PTIX N/A
- Revenue Growth
- OUSTW N/A
- PTIX N/A
- 52 Week Low
- OUSTW N/A
- PTIX $0.43
- 52 Week High
- OUSTW N/A
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- OUSTW N/A
- PTIX 39.26
- Support Level
- OUSTW N/A
- PTIX $0.43
- Resistance Level
- OUSTW N/A
- PTIX $0.52
- Average True Range (ATR)
- OUSTW 0.00
- PTIX 0.05
- MACD
- OUSTW 0.00
- PTIX -0.01
- Stochastic Oscillator
- OUSTW 0.00
- PTIX 6.74
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.